Cr Pharmaceutical

CR Pharmaceutical, headquartered in HK and operating in the Pharmaceutical Preparation Manufacturing industry, has disclosed its carbon emissions and climate commitments.

In 2025, CR Pharmaceutical's reported Scope 1 emissions were 172,130,250 kg CO2e, and Scope 2 emissions were 568,741,300 kg CO2e. For 2024, Scope 1 emissions were 175,023,130 kg CO2e and Scope 2 emissions were 547,436,670 kg CO2e. In 2023, the company reported Scope 1 emissions of 170,536,140 kg CO2e and Scope 2 emissions of 555,112,180 kg CO2e.

Looking back, in 2022, the company's total reported emissions (Scope 1 and 2 combined) were 722,459,800 kg CO2e, with Scope 1 at 160,986,950 kg CO2e and Scope 2 at 613,993,650 kg CO2e. In 2021, total reported emissions were 648,394,790 kg CO2e, comprising 121,763,870 kg CO2e for Scope 1 and 526,630,920 kg CO2e for Scope 2. For 2020, combined Scope 1 and 2 emissions were 540,802,560 kg CO2e. In 2019, combined Scope 1 and 2 emissions were 560,123,090 kg CO2e. In 2018, combined Scope 1 and 2 emissions were 541,956,860 kg CO2e. For 2017, Scope 1 emissions (which were also the combined Scope 1 and 2 total) were 513,058,290 kg CO2e. In 2016, Scope 1 emissions (also the combined Scope 1 and 2 total) were 527,962,720 kg CO2e.

CR Pharmaceutical has set several climate commitments. The company aims to achieve carbon neutrality for both Scope 1 and Scope 2 emissions by 2050. Furthermore, they are targeting a 10% reduction in carbon dioxide emission intensity for Scope 2 by the end of the 14th Five-Year Plan period (2025), relative to 2020 levels. They also plan to decrease the comprehensive energy consumption per RMB 10,000 of added value by 8% for Scope 1 by the end of the 14th Five-Year Plan period (2025), compared to 2020.

The emissions and climate commitments data for CR Pharmaceutical are cascaded from its ultimate parent, China Resources Pharmaceutical Group Limited, as a current subsidiary at cascade level 5.